[Efficacy analysis of selinexor combined with hypomethylating agent in the treatment of refractory/relapsed acute myeloid leukemia exposed to venetoclax]

Zhonghua Xue Ye Xue Za Zhi. 2023 Nov 14;44(11):936-939. doi: 10.3760/cma.j.issn.0253-2727.2023.11.009.

[Article in Chinese]

Authors

J Zhang¹, B Q Song¹, X Kong¹, Y Liu¹, H L Yang¹, L H Zong¹, J Y Kong¹, Y Xu¹, H Y Qiu¹, D P Wu¹

Affiliation

¹ The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.

PMID: 38185524
PMCID: PMC10753257
DOI: 10.3760/cma.j.issn.0253-2727.2023.11.009

No abstract available

MeSH terms

Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
Humans
Hydrazines / therapeutic use
Leukemia, Myeloid, Acute* / drug therapy

Substances

selinexor
venetoclax
Bridged Bicyclo Compounds, Heterocyclic
Hydrazines

Grants and funding

基金项目：国家自然科学基金（82020108003、81730003）；国家重点研发计划（2019YFC0840604）；江苏省自然科学基金（BK20201168）；江苏省老年健康科研课题（LKM2023015）